Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

The recent launch of Ebglyss, a new product in the market since December 2023, has already achieved over EUR 20 million in sales, primarily in Germany. Almirall is also making strides in R&D ...

The recent launch of Ebglyss, a new product in the market since December 2023, has already achieved over EUR 20 million in sales, primarily in Germany. Almirall is also making strides in R&D, with ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and ...

Eli Lilly announced positive results from its Phase 3b study of Ebglyss, which focused on patients with moderate-to-severe atopic dermatitis. Patients had been previously treated with Dupixent ...